FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020865074> ?p ?o ?g. }

• W2020865074 endingPage "1580" @default.
• W2020865074 startingPage "1574" @default.
• W2020865074 abstract "Vascular endothelial growth factor (VEGF) plays a key role in the development of both proliferative diabetic retinopathy (PDR) and diabetic macular oedema (DMO). In recent years, anti-VEGF agents have emerged as new approaches to the treatment of these devastating diabetic complications. Although Phase III studies in the diabetic population are needed, intravitreal anti-VEGF therapy is currently being used in clinical practice. Intravitreal injection is an effective means of delivering anti-VEGF drugs to the retina. However, this is an invasive procedure associated with potentially serious complications, such as endophthalmitis or retinal detachment, which may be significant for patients requiring serial treatment over many years. In addition, although delivered within the vitreous, anti-VEGF drugs could pass into the systemic circulation, which could potentially result in hypertension, proteinuria, increased cardiovascular events and impaired wound healing. Pegaptanib, ranibizumab and bevacizumab are the currently available anti-VEGF agents. Ranibizumab and bevacizumab block all VEGF isoforms, thus impairing both physiological and pathological neovascularisation. Pegaptanib only blocks the VEGF165 isoform, and would therefore seem the best option for avoiding systemic adverse effects in diabetic patients, although this remains to be demonstrated in clinical trials. In this regard, head-to-head studies designed to evaluate not only the efficacy, but also the systemic adverse effects of these drugs in a high-risk population such as diabetic patients are warranted." @default.
• W2020865074 created "2016-06-24" @default.
• W2020865074 creator A5017014718 @default.
• W2020865074 creator A5091908088 @default.
• W2020865074 date "2008-04-11" @default.
• W2020865074 modified "2023-10-18" @default.
• W2020865074 title "Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy" @default.
• W2020865074 cites W1526282761 @default.
• W2020865074 cites W1559170621 @default.
• W2020865074 cites W1802218256 @default.
• W2020865074 cites W1963705625 @default.
• W2020865074 cites W1965259073 @default.
• W2020865074 cites W1969169427 @default.
• W2020865074 cites W1971945408 @default.
• W2020865074 cites W1972242350 @default.
• W2020865074 cites W1975032911 @default.
• W2020865074 cites W1976903522 @default.
• W2020865074 cites W1981608508 @default.
• W2020865074 cites W1985043086 @default.
• W2020865074 cites W1986929568 @default.
• W2020865074 cites W1987699263 @default.
• W2020865074 cites W1990599056 @default.
• W2020865074 cites W1991120368 @default.
• W2020865074 cites W1991843154 @default.
• W2020865074 cites W1996702513 @default.
• W2020865074 cites W2010456451 @default.
• W2020865074 cites W2011046688 @default.
• W2020865074 cites W2020224800 @default.
• W2020865074 cites W2024725915 @default.
• W2020865074 cites W2027142859 @default.
• W2020865074 cites W2029126623 @default.
• W2020865074 cites W2033905464 @default.
• W2020865074 cites W2038598946 @default.
• W2020865074 cites W2045390750 @default.
• W2020865074 cites W2046507292 @default.
• W2020865074 cites W2048818094 @default.
• W2020865074 cites W2057651652 @default.
• W2020865074 cites W2069826874 @default.
• W2020865074 cites W2072431413 @default.
• W2020865074 cites W2075678437 @default.
• W2020865074 cites W2076270591 @default.
• W2020865074 cites W2077130806 @default.
• W2020865074 cites W2085366579 @default.
• W2020865074 cites W2085712747 @default.
• W2020865074 cites W2087780877 @default.
• W2020865074 cites W2088562953 @default.
• W2020865074 cites W2096735172 @default.
• W2020865074 cites W2098155102 @default.
• W2020865074 cites W2098444281 @default.
• W2020865074 cites W2098582960 @default.
• W2020865074 cites W2099927130 @default.
• W2020865074 cites W2103965396 @default.
• W2020865074 cites W2107436171 @default.
• W2020865074 cites W2120472250 @default.
• W2020865074 cites W2123617249 @default.
• W2020865074 cites W2124415048 @default.
• W2020865074 cites W2145946836 @default.
• W2020865074 cites W2150893441 @default.
• W2020865074 cites W2151129590 @default.
• W2020865074 cites W2166926836 @default.
• W2020865074 cites W2171524333 @default.
• W2020865074 cites W2189568502 @default.
• W2020865074 cites W2314927739 @default.
• W2020865074 cites W2612281319 @default.
• W2020865074 cites W3122152400 @default.
• W2020865074 cites W51136706 @default.
• W2020865074 doi "https://doi.org/10.1007/s00125-008-0989-9" @default.
• W2020865074 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18404258" @default.
• W2020865074 hasPublicationYear "2008" @default.
• W2020865074 type Work @default.
• W2020865074 sameAs 2020865074 @default.
• W2020865074 citedByCount "194" @default.
• W2020865074 countsByYear W20208650742012 @default.
• W2020865074 countsByYear W20208650742013 @default.
• W2020865074 countsByYear W20208650742014 @default.
• W2020865074 countsByYear W20208650742015 @default.
• W2020865074 countsByYear W20208650742016 @default.
• W2020865074 countsByYear W20208650742017 @default.
• W2020865074 countsByYear W20208650742018 @default.
• W2020865074 countsByYear W20208650742019 @default.
• W2020865074 countsByYear W20208650742020 @default.
• W2020865074 countsByYear W20208650742021 @default.
• W2020865074 countsByYear W20208650742022 @default.
• W2020865074 countsByYear W20208650742023 @default.
• W2020865074 crossrefType "journal-article" @default.
• W2020865074 hasAuthorship W2020865074A5017014718 @default.
• W2020865074 hasAuthorship W2020865074A5091908088 @default.
• W2020865074 hasBestOaLocation W20208650741 @default.
• W2020865074 hasConcept C118487528 @default.
• W2020865074 hasConcept C126322002 @default.
• W2020865074 hasConcept C134018914 @default.
• W2020865074 hasConcept C167734588 @default.
• W2020865074 hasConcept C197934379 @default.
• W2020865074 hasConcept C2776694085 @default.
• W2020865074 hasConcept C2777025900 @default.
• W2020865074 hasConcept C2777512022 @default.
• W2020865074 hasConcept C2777802072 @default.
• W2020865074 hasConcept C2779742858 @default.

• next